Ratings JW Pharmaceutical Corporation

Equities

A001060

KR7001060003

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-12 pm EDT			5-day change	1st Jan Change
30,100 ^KRW	-1.47%		-0.82%	-15.33%

Mar. 14	JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 22	CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's profit outlook over the next few years is a strong asset.
The company's attractive earnings multiples are brought to light by a P/E ratio at 9.85 for the current year.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JW PHARMACEUTICAL CORPORATION	-15.33%	520M	-
ELI LILLY AND COMPANY	+29.98%	684B	C+
NOVO NORDISK A/S	+30.34%	568B	B
JOHNSON & JOHNSON	-3.52%	361B	C+
MERCK & CO., INC.	+18.59%	329B	B-
ABBVIE INC.	+4.07%	284B	C+
ASTRAZENECA PLC	+16.21%	240B	B+
NOVARTIS AG	+9.66%	208B	B-
ROCHE HOLDING AG	-6.83%	200B	A+
AMGEN INC.	+7.09%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes